Eli Lilly acquires three vaccine startups, expanding into infectious disease beyond weight loss drugs
Eli Lilly is set to purchase three vaccine companies—Curevo, LimmaTech, and one yet to be identified—to enhance its focus on treating infectious diseases. These acquisitions will provide Lilly with vaccines aimed at shingles, bacterial infections, and the Epstein-Barr virus. This initiative represents a significant shift from its successful weight loss medications. The acquisitions reflect Lilly's strategy to broaden its product offerings and engage in the vaccine sector, which has gained traction following the pandemic. Financial details remain undisclosed. This decision arrives as Lilly confronts challenges in maintaining growth due to increasing competition in the obesity medication market.
Key facts
- Eli Lilly is acquiring three vaccine startups.
- The startups are Curevo, LimmaTech, and an unnamed company.
- Target diseases include shingles, bacterial pathogens, and Epstein-Barr virus.
- The expansion goes beyond Lilly's weight loss drug portfolio.
- Financial terms were not disclosed.
- The acquisitions aim to diversify Lilly's pipeline.
- The vaccine market has seen renewed interest post-pandemic.
- Lilly faces competition in the obesity drug space.
Entities
Institutions
- Eli Lilly
- Curevo
- LimmaTech
Sources
- Quartz —